The Esophacoil stent for malignant esophageal obstruction

W. Mayoral, D. E. Fleischer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Esophageal cancer is the seventh most common cause of cancerrelated deaths in men in the United States. For a disease in which 60% of patients are incurable at presentation, palliative therapy is the main treatment option. Palliative measures include surgery, radiation therapy, chemotherapy, photodynamic therapy, endoscopic dilation, endoscopic ablation, and the use of endoscopic prostheses. This article reviews the characteristics, technique, efficacy, and complications of the Esophacoil stent for malignant esophageal strictures.

Original languageEnglish (US)
Pages (from-to)423-430
Number of pages8
JournalGastrointestinal Endoscopy Clinics of North America
Volume9
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

Esophageal Stenosis
Photochemotherapy
Esophageal Neoplasms
Palliative Care
Prostheses and Implants
Stents
Dilatation
Cause of Death
Radiotherapy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

The Esophacoil stent for malignant esophageal obstruction. / Mayoral, W.; Fleischer, D. E.

In: Gastrointestinal Endoscopy Clinics of North America, Vol. 9, No. 3, 1999, p. 423-430.

Research output: Contribution to journalArticle

Mayoral, W. ; Fleischer, D. E. / The Esophacoil stent for malignant esophageal obstruction. In: Gastrointestinal Endoscopy Clinics of North America. 1999 ; Vol. 9, No. 3. pp. 423-430.
@article{f8cc043980534ac193baae58738f46e8,
title = "The Esophacoil stent for malignant esophageal obstruction",
abstract = "Esophageal cancer is the seventh most common cause of cancerrelated deaths in men in the United States. For a disease in which 60{\%} of patients are incurable at presentation, palliative therapy is the main treatment option. Palliative measures include surgery, radiation therapy, chemotherapy, photodynamic therapy, endoscopic dilation, endoscopic ablation, and the use of endoscopic prostheses. This article reviews the characteristics, technique, efficacy, and complications of the Esophacoil stent for malignant esophageal strictures.",
author = "W. Mayoral and Fleischer, {D. E.}",
year = "1999",
language = "English (US)",
volume = "9",
pages = "423--430",
journal = "Gastrointestinal Endoscopy Clinics of North America",
issn = "1052-5157",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The Esophacoil stent for malignant esophageal obstruction

AU - Mayoral, W.

AU - Fleischer, D. E.

PY - 1999

Y1 - 1999

N2 - Esophageal cancer is the seventh most common cause of cancerrelated deaths in men in the United States. For a disease in which 60% of patients are incurable at presentation, palliative therapy is the main treatment option. Palliative measures include surgery, radiation therapy, chemotherapy, photodynamic therapy, endoscopic dilation, endoscopic ablation, and the use of endoscopic prostheses. This article reviews the characteristics, technique, efficacy, and complications of the Esophacoil stent for malignant esophageal strictures.

AB - Esophageal cancer is the seventh most common cause of cancerrelated deaths in men in the United States. For a disease in which 60% of patients are incurable at presentation, palliative therapy is the main treatment option. Palliative measures include surgery, radiation therapy, chemotherapy, photodynamic therapy, endoscopic dilation, endoscopic ablation, and the use of endoscopic prostheses. This article reviews the characteristics, technique, efficacy, and complications of the Esophacoil stent for malignant esophageal strictures.

UR - http://www.scopus.com/inward/record.url?scp=0032793217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032793217&partnerID=8YFLogxK

M3 - Article

C2 - 10388857

AN - SCOPUS:0032793217

VL - 9

SP - 423

EP - 430

JO - Gastrointestinal Endoscopy Clinics of North America

JF - Gastrointestinal Endoscopy Clinics of North America

SN - 1052-5157

IS - 3

ER -